You have no items in your cart. Want to get some nice things?Go shopping
Air pollution is becoming an ever increasing health concern for people all over the world. Evidence increasingly suggests that poor diet, including clinical malnutrition may increase the risk for oxidative stress and chronic diseases.[1-7] Nutrition is known to play a significant role in the prevention and management of these same chronic diseases and has been shown to modulate the toxicity of polychlorinated biphenyls (PCBs, found in sealants, paint plasticizers, wood finishes and flame retardants).[2-6] One study has suggested that there may be increased susceptibility to NO2 when someone is in a fasting state  but it is not known if it is the same for other pollutants.
Oxidative stress, resulting from an imbalance between reactive oxidant species and antioxidants, can lead to tissue damage, airway inflammation with increased asthma severity and abnormal immune responses.[9-11] Serum concentrations of antioxidants have been positively associated with FEV1 in people with and without asthma.[12,13] Vitamin, mineral and botanical compounds have been researched in relation to pollutants over the past 20 years.
Vitamin C and E
Observational studies have reported that low vitamin C and vitamin E intakes are associated with a higher prevalence of asthma. Exposure to O3 results in dose dependent depletion of antioxidants vitamin C and E in the skin. Antioxidant supplementation with vitamin C and E above the minimum dietary requirement led to attenuated nasal inflammation and partially restored antioxidant levels in asthmatic patients exposed to high levels of O3 . A meta-analysis of 24 observational studies in children and adults found lower dietary intake (but not serum level) of vitamin E was also significantly associated with increased asthma severity . A review of 15 observational studies (including 3 birth cohorts), suggested that the evidence linking low vitamin E to asthma development was methodologically weak but sufficiently supportive of a potential effect warranting follow-up in clinical trials.
Four RCTs reported that vitamin E-containing antioxidants reduce O3-induced bronchoconstriction in subjects with [19,20] and without [21,22] asthma, suggesting potential protective effects of vitamin E against the detrimental effects of O3. A study in children looked at total antioxidant intake and asthma rates, and there appeared to be a link between higher antioxidant intake (total antioxidant capacity) and diminished sensitivity to inhaled allergens. Children in areas of low traffic pollution displayed a stronger association between sensitivity to allergens and antioxidant capacity. In people with exercise induced asthma, vitamin C and Vitamin E supplement aided recovery by improving flow rates. A London based bidirectional case cross-over study looked at whether individual plasma antioxidant concentrations (uric acid and vitamins C, A, and E) and 10 antioxidant genes could modify the response to PM with respect to hospital admissions for COPD or asthma. Two hundred and thirty four admissions were recorded and the level of PM10 was noted 14 days before and after each event. Combined admission rates were related to a 10 μg/m increase in PM10. Serum vitamin C modified the effect of PM10 on asthma/COPD exacerbations. A similar (although weaker) influence was observed for low levels of uric acid and vitamin E, whereas vitamin A showed no effect modification.
Vitamin D is key to the metabolism of calcium and phosphorus. In adults with Asthma, normal vitamin D levels correlated with improved asthma control and therefore supplementation may play a role in uncontrolled asthmatics with vitamin D deficiency.
Irrespective of the threshold used, in a US cohort, reduced serum or plasma vitamin D concentrations are commonly detected in children and adults particularly in subgroups at high risk for asthma or asthma morbidity.[27,28]
Three population-based studies (two cross-sectional [27,29] and one longitudinal  showed an association between reduced serum vitamin D concentrations and severe disease exacerbations or core measures (eg, hospitalisations) of severe exacerbations in Costa Rican, North American, and Puerto Rican children with asthma. In the most recent of these studies, vitamin D insufficiency or deficiency (a serum 25[OH] D concentration <30 ng/mL) was associated with increased odds of one or more severe asthma exacerbations in the previous year even in non-atopic children. This suggests that vitamin D affects the risk of severe asthma exacerbations through mechanisms other than regulation of allergic immune responses. Reduced vitamin D concentrations are also associated with increased airway smooth muscle mass, decreased lung function, and worse disease control in children with severe, therapy-resistant asthma. A Cochrane database systematic review was undertaken on vitamin D and asthma. Meta-analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use.
The phytochemical curcumin, from turmeric, has been found to be a potent anti-inflammatory agent, and has been studied in regards to its anti-tumour, antifungal and antioxidant properties. Animal models have demonstrated that curcumin is a potent anti-inflammatory agent in the lungs  and that it may also protect against pulmonary fibrosis. A number of studies have suggested that curcumin may have some protective role against the DNA damage caused by arsenic.[36,37] In a pre-clinical renal cancer study, addition of curcumin to cancer cells exhibited a strong potential for protection against diesel exhaust and cisplatin-induced cytotoxicity . Preclinical trials have also shown that curcumin inhibited POP associated cellular and DNA damage.[39,40] It has also reversed nicotine induced liver toxicity in an animal study.
Pre-clinical studies have shown that curcumin can prevent cadmium-induced IL-6 and IL-8 inflammatory secretion by human airway epithelial cells. Cadmium (Cd) is a toxic metal present in the environment and its inhalation can lead to pulmonary disease including lung cancer and COPD. Curcumin could therefore potentially be used to prevent airway inflammation due to cadmium inhalation.
Specifically in COPD, curcumin has been shown in animal models to have a beneficial effect in smooth muscle cells and improve the mean pulmonary artery pressure and right ventricular myocardial infarction (RVMI) through stimulating the suppressor of cytokine signalling (SOCS) -3/JAK2/STAT signalling pathways. In another model, curcumin was shown to suppress chemokines and affect corticosteroid sensitivity in COPD through modulating Histone deacetylase 2 (HDAC2) expression and its effect on histone modification. Another animal model showed that curcumin attenuates alveolar epithelial injury in COPD, which may be partially due to the down-regulation of Protein 66 homologous- collagen homologue (p66Shc). In a randomised, double blinded, parallel group study in patients with mild COPD and raised LDL cholesterol, 90mg curcumin was found to reduce the α1-antitrypsin–low-density lipoprotein (AT-LDL) complex, thus reducing risk of future cardiovascular events.
In other patients, a population based study of 2478 people found that people taking dietary curcumin through eating curry had better pulmonary function. The mean adjusted FEV1 associated with curry intake was 9.2% higher among current smokers, 10.3% higher among past smokers, and 1.5% higher among non-smokers. In 89 patients who had poor pulmonary function due to sulphur mustard, curcumin (1500 mg/day) + piperine (15 mg/day) or a placebo were given for 4 weeks. The active supplement reduced systemic oxidative stress and clinical symptoms, and also improved health related quality of life.
Omega-3 oils (or n-3 polyunsaturated fats-PUFAs) have received much attention due to their ability to reduce inflammation, and for its anti-coagulant properties, thus reducing risk of cardiovascular diseases. Two randomised controlled studies have investigated early life fish oil dietary supplementation in relation to asthma outcomes in children at high risk of atopic disease (at least one parent or sibling had atopy with or without asthma). In a study, powered only to detect differences in cord blood, maternal dietary fish oil supplementation during pregnancy was associated with reduced cytokine release from allergen stimulated cord blood mononuclear cells. However, effects on clinical outcomes at one year, in relation to atopic eczema, wheeze and cough, were marginal. In a second study, fish oil supplementation started in early infancy with or without additional house dust mite avoidance, was associated with a significant reduction in wheeze at 18 months of age. By five years of age fish oil supplementation was not associated with effects on asthma or other atopic diseases. In the absence of any evidence of benefit from the use of fish oil supplementation in pregnancy, the British Thoracic Society SIGN 2016 guidelines do not recommend it as a strategy for primary prevention of childhood asthma.
There are recent studies which use omega-3 oils to combat the effects of pollution. Animal models of fine particle matter pollution, demonstrated that omega-3 oils prevented and improve inflammation caused by these fine particles  with a further pre-clinical study showing that omega-3 oils reduced the oxidative damage in the intestines after heavy metals ingestion .
For the early and milder forms of allergic asthma, dietary supplementation with long-chain polyunsaturated fatty acids (LCPUFA), predominantly fish oil-associated eicosapentaenoic (C20:5 ω-3) and docosahexaenoic acid (C22:6 ω-3), and distinct crop oil-derived fatty acids have been proposed to provide a sustainable treatment strategy.[54,55] C20:5 and C22:6 ω-3 fatty acids inhibit cyclooxygenase (COX) activity and decrease eicosanoid synthesis from amino acids. They also suppress immunoglobulin (Ig) E production and thereby reduce airway inflammation and bronchoconstriction in asthma. In 2002 a Cochrane database review concluded that there was insufficient evidence to recommend fish oil supplementation for the treatment of asthma.
In addition to immune-controlling prostaglandins, leukotrienes, and thromboxanes, specialised mediators, such as lipoxins, resolvins, protectins, and maresins are metabolised from different LCPUFA, which actively resolve inflammation. Where people with asthma are allergic to pollutants and other allergens, omega-3 and some omega 6 oils also act to reduce inflammation, rebuilding fatty acid homeostasis in cellular membranes, modifying eicosanoid metabolic pathways, thus reducing clinical symptoms.[59,60] Most recently, an animal study compared the effects of olive oil, coconut oil and fish oil. Although fish oil protected against O3 induced vascular damage, it increased pulmonary injury/inflammation and impaired lipid transport mechanisms.
In a COPD randomised placebo controlled trial of 86 patients, an omega-3, vitamin D and leucine supplement drink was given to half the group for 4 months alongside high intensity training, whilst the other half undertook the exercise alone. The population had moderate airflow limitation, low diffusion capacity, normal protein intake, low plasma vitamin D, and docosahexaenoic acid. There were significant differences after 4 months favouring the supplement group for body mass, plasma vitamin D, eicosapentaenoic acid, docosahexaenoic acid and number of steps.
Choline is a lipotropic agent involved in several biological functions (eg, neurotransmitter production, signalling lipids, and components of structural membranes), and as a methyl group donor . Dietary sources of choline include meat, liver, eggs, poultry, fish and shellfish, peanuts, and cauliflower. Choline deficiency is associated with neurological disorders, cardiovascular diseases, and inflammation.
Intranasal or oral administration of choline has been shown to reduce the number of eosinophils and reactive oxidant species in bronchoalveolar lavage fluid in a murine model of allergic airway disease. In human studies, 76 asthma patients were recruited and treated with a choline supplement (1500 mg twice) or standard pharmacotherapy for 6 months in two groups. The patients were evaluated by clinical, immunologic and biochemical parameters. The treatment with choline showed significant reduction in symptom/drug score and improvement in FEV1 compared to baseline or standard pharmacotherapy. Choline therapy significantly reduced IL-4, IL-5 and TNF-alpha level as compared to baseline or standard pharmacotherapy after 6 months (p<0.01). Blood eosinophil count and total IgE levels were reduced in both of the treatment groups. In a cross-sectional survey that enrolled 1514 men and 1528 women with no history of cardiovascular disease (the ATTICA Study), fasting blood samples were collected and inflammatory markers were measured. Compared with the lowest tertile of choline intake (<250 mg/d), participants who consumed >310 mg/d had, on average, 22% lower concentrations of C-reactive protein (P < 0.05), 26% lower concentrations of IL-6 (P < 0.05), and 6% lower concentrations of tumour necrosis factor-alpha (P < 0.01). These findings were independent of various sociodemographic, lifestyle, and clinical characteristics of the participants. This suggests that choline might attenuate allergic inflammation in general and airway inflammation in particular.
Read the full paper as a pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930792/pdf/12931_2018_Article_785.pdf
- Majkova Z, Oesterling E, Toborek M, Hennig B. Impact of nutrition on PCB toxicity. Environ Toxicol Pharmacol. 2008;25:192–196. [PubMed]
- Ruzzin J, Petersen R, Meugnier E, Madsen L, Lock EJ, Lillefosse H, et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect. 2010;118:465–471. [PMC free article] [PubMed]
- Hennig B, Toborek M, Reiterer G, et al. Nutrition modulates PCB toxicity: Implications in atherosclerosis. In: Hansen LG, Robertson LW, et al., editors. Human and Environmental Disposition and Toxicology. 2008. pp. 165–171.
- Watkins BA, Hannon K, Ferruzzi M, Li Y. Dietary PUFA and flavonoids as deterrents for environmental pollutants. J Nutr Biochem. 2007;18:196–205. [PubMed]
- Ludewig G, Robertson LW. Polychlorinated biphenyls (PCBs) as initiating agents in hepatocellular carcinoma. Cancer Lett. 2013;334:46–55.[PMC free article] [PubMed]
- Hennig B, Hammock BD, Slim R, Toborek M, Saraswathi V, Robertson LW. PCB-induced oxidative stress in endothelial cells: modulation by nutrients. Int J Hyg Environ Health. 2002;205:95–102. [PubMed]
- Pocernich CB, Lange ML, Sultana R, Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimer’s disease. Curr Alzheimer Res. 2011;8:452–469. [PubMed]
- Ward-Caviness CK, Breitner S, Wolf K, Cyrys J, Kastenmüller G, Wang-Sattler R, et al. Short-term NO2 exposure is associated with long-chain fatty acids in prospective cohorts from Augsburg, Germany: results from an analysis of 138 metabolites and three exposures. Int J Epidemiol. 2016;45:1528–1538. [PubMed]
- Caramori G, Papi A. Oxidants and asthma. Thorax. 2004;59:170–173.[PMC free article] [PubMed]
- Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol. 2008;8:49–56.[PubMed]
- Katsoulis K, Kontakiotis T, Leonardopoulos I, Kotsovili A, Legakis IN, Patakas D. Serum total antioxidant status in severe exacerbation of asthma: correlation with the severity of the disease. J Asthma. 2003;40:847–854.[PubMed]
- Schunemann HJ, Grant BJ, Freudenheim JL, Muti P, Browne RW, Drake JA, et al. The relation of serum levels of antioxidant vitamins C and E, retinol and carotenoids with pulmonary function in the general population. Am J Respir Crit Care Med. 2001;163:1246–1255. [PubMed]
- Ochs-Balcom HM, Grant BJ, Muti P, Sempos CT, Freudenheim JL, Browne RW, et al. Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Eur J Clin Nutr. 2006;60:991–999. [PubMed]
- Tricon S, Willers S, Smit HA, Burney PG, Devereux G, Frew AJ, et al. Nutrition and allergic disease. Clin Exp Allergy Rev. 2006;6(5):117–188.
- Mancebo SE, Wang SQ. Recognizing the impact of ambient air pollution on skin health. J Eur Acad Dermatol Venereol. 2015;29:2326–2332.[PMC free article] [PubMed]
- Sienra-Monge JJ, Ramirez-Aguilar M, Moreno-Macias H, Reyes-Ruiz NI, Del Río-Navarro BE, Ruiz-Navarro MX, et al. Antioxidant supplementation and nasal inflammatory responses among young asthmatics exposed to high levels of ozone. Clin Exp Immunol. 2004;138:317–322.[PMC free article] [PubMed]
- Allen S, Britton JR, Leonardi-Bee JA. Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis. Thorax. 2009;64:610–619. [PubMed]
- Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis. J Allergy Clin Immunol. 2011;127:724–733. [PubMed]
- Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, Téllez-Rojo MM, Moreno-Macías H, Reyes-Ruiz NI, et al. Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants. Am J Respir Crit Care Med. 2002;166:703–709. [PubMed]
- Trenga CA, Koenig JQ, Williams PV. Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma. Arch Environ Health. 2001;56:242–249. [PubMed]
- Romieu I, Meneses F, Ramirez M, Ruiz S, Perez Padilla R, Sienra JJ, et al. Antioxidant supplementation and respiratory functions among workers exposed to high levels of ozone. Am J Respir Crit Care Med. 1998;158:226–232. [PubMed]
- Grievink L, Zijlstra AG, Ke X, Brunekreef B. Double-blind intervention trial on modulation of ozone effects on pulmonary function by antioxidant supplements. Am J Epidemiol. 1999;149:306–314. [PubMed]
- Gref A, Rautiainen S, Gruzieva O, Håkansson N, Kull I, Pershagen G, et al. Dietary total antioxidant capacity in early school age and subsequent allergic disease. Clin Exp Allergy. 2017;47:751–759. [PMC free article][PubMed]
- Kurti SP, Murphy JD, Ferguson CS, Brown KR, Smith JR, Harms CA. Improved lung function following dietary antioxidant supplementation in exercise-induced asthmatics. Respir Physiol Neurobiol. 2016;220:95–101.[PubMed]
- Canova C, Dunster C, Kelly FJ, Minelli C, Shah PL, Caneja C, et al. PM10-induced hospital admissions for asthma and chronic obstructive pulmonary disease: the modifying effect of individual characteristics. Epidemiology. 2012;23:607–615. [PubMed]
- Boonpiyathad T, Chantveerawong T, Pradubpongsa P, Sangasapaviliya A. Serum Vitamin D Levels and Vitamin D Supplement in Adult Patients with Asthma Exacerbation. J Allergy (Cairo). 2016;2016:4070635.[PMC free article] [PubMed]
- Brehm JM, Acosta-Perez E, Klei L, Roeder K, Barmada M, Boutaoui N, et al. Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. Am J Respir Crit Care Med. 2012;186:140–146.[PMC free article] [PubMed]
- Paul G, Brehm JM, Alcorn JF, Holguin F, Aujla SJ, Celedon JC. Vitamin D and asthma. Am J Respir Crit Care Med. 2012;185:124–132.[PMC free article] [PubMed]
- Brehm JM, Celedón JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med. 2009;179:765–771.[PMC free article] [PubMed]
- Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol. 2010;126:52–58. [PMC free article] [PubMed]
- Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med. 2011;184:1342–1349. [PMC free article] [PubMed]
- Martineau AR, Cates CJ, Urashima M, Jensen M, Griffiths AP, Nurmatov U, et al. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2016;9:CD011511. [PubMed]
- Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75. [PubMed]
- Yang X, Lv JN, Li H, Jiao B, Zhang QH, Zhang Y, et al. Curcumin reduces lung inflammation via Wnt/β-catenin signaling in mouse model of asthma. J Asthma. 2017;54:335–340. [PubMed]
- Chauhan PS, Dash D, Singh R. Intranasal Curcumin Inhibits Pulmonary Fibrosis by Modulating Matrix Metalloproteinase-9 (MMP-9) in Ovalbumin-Induced Chronic Asthma. Inflammation. 2017;40:248–258. [PubMed]
- Khan S, Vala JA, Nabi SU, Gupta G, Kumar D. Telang et al. Protective effect of curcumin against arsenic-induced apoptosis in murine splenocytes in vitro. J Immunotoxicol. 2012;9:148–159. [PubMed]
- Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol. 2010;29:513–524. [PubMed]
- Waly MI, Ali BH, Nemmar A. Acute effects of diesel exhaust particles and cisplatin on oxidative stress in cultured human kidney (HEK 293) cells, and the influence of curcumin thereon. Toxicol In Vitro. 2013;27:2299–2304.[PubMed]
- Çelik A, Eke D, Ekinci SY, Yıldırım S. The protective role of curcumin on perfluorooctane sulfonate-induced genotoxicity: single cell gel electrophoresis and micronucleus test. Food Chem Toxicol. 2013;53:249–255. [PubMed]
- Eke D, Çelik A. Curcumin prevents perfluorooctane sulfonate-induced genotoxicity and oxidative DNA damage in rat peripheral blood. Drug Chem Toxicol. 2016;39:97–103. [PubMed]
- Salahshoor M, Mohamadian S, Kakabaraei S, Roshankhah S, Jalili C. Curcumin improves liver damage in male mice exposed to nicotine. J Tradit Complement Med. 2016;6:176–183. [PMC free article] [PubMed]
- Rennolds J, Malireddy S, Hassan F, Tridandapani S, Parinandi N, Boyaka PN, et al. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Biochem Biophys Res Commun. 2012;417:256–261. [PMC free article] [PubMed]
- Lin X, Chen Y, Effect LZ. its molecular mechanisms of curcumin on pulmonary artery smooth muscle cells in rat model with chronic obstructive pulmonary disease. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016;45:469–476. [PubMed]
- Gan L, Li C, Wang J, Guo X. Curcumin modulates the effect of histone modification on the expression of chemokines by type II alveolar epithelial cells in a rat COPD model. Int J Chron Obstruct Pulmon Dis. 2016;11:2765–2773. [PMC free article] [PubMed]
- Zhang M, Xie Y, Yan R, Shan H, Tang J, Cai Y, et al. Curcumin ameliorates alveolar epithelial injury in a rat model of chronic obstructive pulmonary disease. Life Sci. 2016;164:1–8. [PubMed]
- Funamoto M, Sunagawa Y, Katanasaka Y, Miyazaki Y, Imaizumi A, Kakeya H, et al. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2029–2034. [PMC free article] [PubMed]
- Ng TP, Niti M, Yap KB, Tan WC. Curcumins-Rich Curry Diet and Pulmonary Function in Asian Older Adults. Shi W, ed. PLoS One. 2012;7:e51753. [PMC free article] [PubMed]
- Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial. J Diet Suppl. 2016;13:93–105. [PubMed]
- Dunstan JA, Mori TA, Barden A, Beilin LJ, Taylor AL, Holt PG, et al. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy. a randomized, controlled trial. J Allergy Clin Immunol. 2003;112(6):1178–1184. [PubMed]
- Mihrshahi S, Peat JK, Webb K, Oddy W, Marks GB, Mellis CM, et al. Effect of omega-3 fatty acid concentrations in plasma on symptoms of asthma at 18 months of age. Pediatr Allergy Immunol. 2004;15(6):517–522.[PubMed]
- British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. In: The British Thoracic Society; 2016. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016. Accessed 1 Feb 2018.
- Li XY, Hao L, Liu YH, Chen CY, Pai VJ, Kang JX. Protection against fine particle-induced pulmonary and systemic inflammation by omega-3 polyunsaturated fatty acids. Biochim Biophys Acta. 2017;1861:577–584.[PubMed]
- Zhang F, Yu H, Ni X Zhu J, Wang S, Shen S. Effect of ω-3 polyunsaturated fatty acids on the growth of IEC-6 cells injured by heavy metals. Biomed Rep. 2016;4:635–641. [PMC free article] [PubMed]
- Biltagi MA, Baset AA, Bassiouny M, Kasrawi MA, Attia M. Omega-3 fatty acids, vitamin c and Zn supplementation in asthmatic children: a randomized controlled study. Acta Paediatr. 2009;98:737–742. [PubMed]
- Lundstrom SL, Yang J, Brannan JD, Haeggstrom JZ, Hammock BD, Nair P, et al. Lipid Mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids. Mol Food Res. 2013;57:1378–1389. [PMC free article] [PubMed]
- Guidetti AM, Cagnozzo R. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases. Prostaglandins. Other Lipid Mediat. 2012;99:57–67. [PubMed]
- Yates CM, Calder PC, Ed RG. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther. 2014;141:272–282. [PubMed]
- Thien FCK, De Luca S, Woods RK, Abramson MJ. Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database Syst Rev. 2002;2 10.1002/14651858.CD001283. [PubMed]
- Barros R, Moreira A, Fonseca J, Ddelgado I, Castel-Branco MG, Haahtela T, et al. Dietary intake of alpha linoleic acid and low ratio of n-6: n-3 PUFA are associated with decreased exhaled NO and improved asthma control. Br J Nutr. 2011;106:441–450. [PubMed]
- Beermann C, Neumann S, Fußbroich D, Zielen S, Schubert R. Combinations of distinct long-chain polyunsaturated fatty acid species for improved dietary treatment against allergic bronchial asthma. Nutrition. 2016;32:1165–1170. [PubMed]
- Snow SJ, Cheng WY Henriquez A, Hodge M, Bass V, Nelson GM, et al. Ozone-Induced Vascular Contractility and Pulmonary Injury are Differentially Impacted by Diets Enriched with Coconut Oil, Fish Oil, and Olive Oil. Toxicol Sci. 2018; 10.1093/toxsci/kfy003. [PubMed]
- van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols AMWJ. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle. 2017;8:748–758. [PMC free article] [PubMed]
- Blusztajn JK,Choline a vital amine. Science. 1998;281:794–5. [PubMed]
- Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutrition Rev. 2009;67:615–623. [PMC free article] [PubMed]
- Mehta AK, Arora N, Gaur SN, Singh BP. Choline supplementation reduces oxidative stress in mouse model of allergic airway disease. Eur J Clin Invest. 2009;39:934–941. [PubMed]
- Mehta AK, Singh BP, Arora N, Gaur SN. Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma. Immunobiology. 2010;215:527–534. [PubMed]
- Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr. 2008;87:424–430. [PubMed]
Diet and food supplements are of increasing interest in view of their potential in obesity management. Xanthohumol (XN) is a prenylated flavonoid found in hops, which have been used since ancient times as a medicinal plant. Traditional medicinal indications included the treatment of anxiety and insomnia, mild pain reduction or combating dyspepsia. Today, hops are used in the manufacturing of beer and female infertile plants, e.g. Humulus lupulus L, are cultivated especially for brewing. Biologically active substances, which are important for brewing, are concentrated inside hop cones in lupulin glands which contain hop resins, bitter acids, essential oils and prenylated flavonoids. For humans, beer is the major dietary source of XN. The beer content of XN varies significantly depending on the type of beer (in the range of 0.052–0.628 mg/l).
XN has also been proven to exert antioxidative, chemopreventive, and anti-inflammatory effects. It inhibits metabolic activation of food-borne carcinogens, induces phase 2 enzymes related to detoxification of xenobiotics, inhibits the PGE2 or NO production (linked to prevention of carcinogenesis),[6-8] exerts anti-tumour activity in hypoxic tumour cells. Recent studies investigating XN have also focused on the prevention and treatment of cancer.[10,11] XN has been shown to block T-cell lymphoblastic lymphomagenesis through reduction of STAT5 phosphorylation and gene up-regulated in the non-obese-diabetic STAT5bTg mice. Xanthohumol also inhibits the proliferation of lymphoma cells and IL-2 induced proliferation and cell cycle progression in mouse splenic T cells. XN exhibits anti-proliferative activity against breast, colon and ovarian cancer cell lines and is a potent inducer of chemoprevention enzymes regulated by the antioxidant response element.[14,15] So called ‘carcinoid’ cancer cell lines have also been treated with XN and this showed antiproliferative effects.
Furthermore, the female benefits of hop extracts are under investigation for their oestrogenic and are being used by women as dietary supplements and alternatives to conventional hormone replacement therapy for the management of menopausal hot flushes. One group investigated the pharmacokinetics of XN together with other three prenylated phenols following oral administration to menopausal women and reported that short-term consumption of a chemically and biologically standardized preparation of spent hops is safe for women and that once daily dosing might be appropriate. Xanthohumol and the other prenylated phenols showed long half-lives but no acute toxicity.
There is some evidence, including in vitro and animal studies that XN might exert beneficial effect in hyperlipidaemia. XN inhibits diacylglycerol acyltransferase (DGAT) and the expression of DGAT or microsomal triglyceride transfer protein (MTP) related to the lowering effects of triglyceride and apolipoprotein B.[19, 20]
XN has been suggested to have anti-atherogenic bioactivity as it is reported to decrease apolipoprotein B (apoB) secretion, inhibit triglyceride (TG) synthesis and prevent LDL oxidation in vitro. Furthermore, previous studies showed that XN reduced plaque formation in aortic lesions via reduced lipogenesis and increased faecal cholesterol excretion in apolipoprotein (apoE)-deficient mice. Moroever, XN has been reported to increase HDL cholesterol via cholesteryl ester transfer protein (CETP) inhibition in a CETP-transgenic mouse model.
Previous studies [20, 24] have shown that XN inhibits diacylglycerol acyltransferase (DGAT) activity or the expression of DGAT or microsomal triglyceride transfer protein in HepG2 cells. Those activities suggest that XN exerts TG lowering effect and amelioration of metabolic disorders in viscera. In 3T3-L1 adipocytes, Yang et al. reported reduced lipid content and decreased adipocyte marker proteins after incubation with XN. However, there have not been sufficient experiments to allow us to ascertain the molecular mechanism through which XN ameliorates metabolic disorders in vivo. Nozawa,  found that XN activated farnesoid X receptor (FXR) in vitro and modulated genes involved in lipid or glucose metabolism in mice.
Hirata et al recently investigated the effects of XN on reverse cholesterol transport in vivo and HDL cholesterol levels using a hamster model. They showed that XN improves the cholesterol efflux capacity of HDL and further enhanced in vivo reverse cholesterol transport from macrophages to faeces in hamsters. They also suggested that it may be possible to extend these findings to humans, since hamsters, like humans, express CETP, suggesting that they have a similar RCT system to humans.
Another group demonstrated that addition of XN to western-type diet ameliorates atherosclerotic plaque formation in ApoE−/− mice by positively affecting plasma cholesterol and MCP-1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase (AMPK). Therefore, the atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase.
Increasing cases of obesity has become a serious social problem in developed countries especially as obesity is closely related to the development of various lifestyle diseases.[28,29] Obesity develops when energy intake, in the form of food, exceeds energy expenditure  and is primarily characterized by excessive adiposity. There are two functionally and morphologically distinct types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT), both of which are mediators of energy homeostasis. In response to specific stimuli, WAT can acquire brown-like characteristics, which is called “beiging” and has been demonstrated in vivo  and in vitro  to improve the metabolic profile and increase thermogenesis.
There is some evidence derived from in vitro and animal studies that XN exerts anti-obesity effects, even if some controversy still exits.
Xanthohumol (XN) has been reported to exert anti-obesity effects in Zucker rats [34,35] and in various mouse strains.[3,36,37] Miranda et al. demonstrated that XN has bioactivities potentially useful for countering the metabolic aberrations of Metformin. In details, they showed that treating high fat diet (HFD)-fed C57BL/6 J mice orally with XN (60 mg/kg/day) reduced their plasma low-density lipoprotein-cholesterol (LDL-c, −80%), interleukin-6 (IL-6, −78%), HOMA-IR (−52%), leptin (−41%), and plasma levels of the LDL receptor-degrading enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) (−44%) levels compared to those of vehicle/HFD control. The same group found that XN and its hydrogenated derivatives, α,β-dihydro-XN (DXN) and tetrahydro-XN (TXN) improve glucose tolerance and cognitive function in HFD-fed mice. Unlike XN, DXN and TXN are unable to form the estrogenic metabolite, 8-PN, and they themselves have negligible affinity for estrogen receptors. Therefore, the XN derivatives DXN and TXN have potential to prevent or treat the neuro-metabolic impairments associated with HFD-induced obesity and metformin without risk of liver injury and adverse oestrogenic effects.
Takahashi and collegues, in their recent study in animals, observed that dietary purified XN exerted anti-obesity effects by regulating lipid metabolism and inhibiting intestinal fat absorption in KK-Ay mice, thus, they suggested that XN may exert anti-obesity effects. Another team showed that XN suppressed the increase in body weight, mesenteric WAT, liver weight, and triacylglycerol levels in the plasma and liver through regulation of hepatic fatty acid metabolism and inhibition of intestinal fat absorption in Wistar rats fed a high-fat diet. The anti-obesity effects of XN are partly mediated by AMPK signalling pathway suggesting that XN may have potential therapeutic implications for obesity. Yang and collegues confirmed the anti-adipogenic effects of XN under in vitro conditions. Conversely, Mendes and colleagues claimed that XN does not improve the metabolic profile linked to obesity as XN may reduce adipocyte number, contributing to adipocyte hypertrophy.
The prevalence of T2DM, which is often associated to obesity, has increased dramatically in the last decades. T2DM is a chronic, multifactorial and progressive disease, which affects more than 300 million people worldwide. Diabetes is characterized by hyperglycemia due to a deficiency in insulin production and/or its resistance, which contributes to endothelial dysfunction, resulting in macro and microvascular complications.[42,43] Imbalance in kidney and heart neovascularization is seen in T2DM patients. Costa and colleagues reported that XN consumption reduced angiogenesis, vascular endothelial growth-factor receptor (VEGFR)-2 expression/activity, levels of VEGF-B and its receptors (i.e. VEGFR1 and neuropilin-1), VEGF-A and phosphofructokinase-2/fructose-2,6-bisphosphatase-3 enzyme expression, a metabolic marker present in endothelial tip cells in T2DM mice kidney. Altogether, these findings suggest that XN prevent angiogenic impairment and metabolic pathways that are implicated in the pathogenesis of T2DM, being promising compounds to mitigate the increasing number of diabetic patients and inherent health care costs. Another study by Costa and colleagues in the same year found that XN protects mice against the development of T2DM metabolic-related complications. XN was reported to reduce body weight gain, prevent insulin resistance and modulate lipid and glucose metabolic pathways, being these effected mediated by a metabolic switch from fatty acid synthesis to oxidation and by promoting muscle glucose uptake. Furthermore, Nozawa, in their in vitro and in vivo study, reported potential beneficial effects of XN on amelioration of metabolic disorders via farnesoid X receptor (FXR) action and showed the possibility for developing such FXR modulators as functional nutrients in the therapy or prevention of metabolic syndromes.
Legette et al. recently conducted a study in healthy men and women to determine basic pharmacokinetics (PK) parameters for XN with the aim to establish dose-concentration relationships and to predict dose-effect relationships in humans diagnosed with metabolic syndrome. To our knowledge, this is the first study that reports human PK parameters for XN. Xanthohumol PK shows a distinct biphasic absorption pattern with XN and isoxanthohumol (IX) conjugates being the major circulating metabolites following oral consumption of XN in humans. XN metabolism appears to be similar between animals and humans, thus allowing for translation of animal study findings to future clinical work. Based on these and previous findings [34,46] the selection of effective doses to be utilized in future clinical studies aimed at improving lipid and glucose metabolism in humans diagnosed with metabolic syndrome should be possible.
- Zanoli P, Zavatti, M. 2008. Pharmacognostic and pharmacological profile of Humulus lupulus L. J. Ethnopharmacol 116: 383–396.
- Chen L, Zhao Q, Jin H, Zhang X, Xu Y et al. 2010. Determination of xanthohumol in beer based on cloud point extraction coupled with high performance liquid chromatography. Talanta 81: 692–697.
- Nozawa H. 2005. Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem Biophys Res Commun 336(3): 754-61.
- Miranda CL, Yang YH, Henderson MC, Stevens JF, Santana-Rios G, et al. 2000. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline, mediated by cDNAexpressed human CYP1A2, Drug Metab. Dispos. 28: 1297–1302.
- Miranda CL, Aponso GL, Stevens JF, Deinzer ML, Buhler DR. 2000. Prenylated chalcones and flavanones as inducers of quinine reductase in mouse Hepa 1c1c7 cells. Cancer Lett 149: 21–29
- Zhao F, Nozawa H, Daikonnya A, Kondo K, Kitanaka S. 2003. Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol Pharm Bull 26: 61–65.
- Zhao F, Watanabe Y, Nozawa H, Daikonnya A, Kondo K, et al. 2005. Prenylflavonoids and phloroglucinol derivatives from hops (Humulus lupulus). J Nat Prod 68: 43–49.
- Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, et al. 2002. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther 1: 959–969.
- Goto K, Asai T, Hara S, Namatame I, Tomoda H, et al. 2005. Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett 219: 215–22210.
- Chen PH, Chang CK, Shih CM, Cheng CH, Lin CW, et al.: The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death. Neuropharmacology 110, 362–375, 2016. doi: 10.1016/j.neuropharm.2016.07.038. [PUBMED]
- Dokduang H, Yongvanit P, Namwat N, Pairojkul C, Sangkhamanon S, et al.: Xanthohumol inhibits STAT3 activation pathway leading to growth suppression and apoptosis induction in human cholangiocarcinoma cells. Oncol Rep 35, 2065–2072, 2016. doi: 10.3892/or.2016.4584. [PUBMED]
- Chen B, Yi B, Mao R, Liu H, Wang J et al.: Enhanced T Cell Lymphoma in NOD.Stat5b Transgenic Mice Is Caused by Hyperactivation of Stat5b in CD8+ Thymocytes. PLoS ONE 8, e56600, 2013. doi: 10.1371/journal.pone.0056600. [PUBMED]
- Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, et al.: Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 49, 844-50, 2005. doi: 10.1002/mnfr.200500045 [PUBMED].
- Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, et al. 1999. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol 37: 271–285.
- Dietz BM, Kang YH, Liu G, Eggler AL, Yao P, et al. 2005. Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol 18: 1296–1305.
- McManus C M, Seiler BA, Rose SL, Chen H, Kunnimaliyaan M. 2010. Xanthohumol, a novel plant extract, alters neuroendocrine phenotype and inhibits growth of carcinoid cell lines. Poster abstract, NANETS.
- Chadwick LR, Pauli GF, Farnsworth NR. 2006. The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties. Phytomedicine 13: 119131.
- van Breemen RB, Yuan Y, Banuvar S, Shulman LP, Qiu X, et al. 2014. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol Nutr Food Res 58(10): 1962-9.
- Tabata N, Ito M, Tomoda H, Omura S. 1997. Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus. Phytochemistry 46: 683–687.
- Casaschi A, Maiyoh GK, Rubio BK, Li RW, Adeli K, et al. 2004. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J Nutr 134: 1340–1346.
- Liu M, Hansen PE, Wang G, Qiu L, Dong J, et al. 2015. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules. 20: 754-79.
- Doddapattar P, Radović B, Patankar JV, Obrowsky S, Jandl K, et al. 2013. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res 57: 1718-28.
- Hirata H, Yimin, Segawa S, Ozaki M, Kobayashi N, et al. 2012. Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice. PLoS One 7: e49415.
- Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497–509.
- Yang JY, Della-Fera MA, Rayalam S, Baile CA. 2007. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis 12: 1953–1963.
- Hirata H, Uto-Kondo H, Ogura M, Ayaori M, Shiotani K, et al. 2017. Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport. J Nutr Biochem 47: 29-34.
- Doddapattar P, Radović B, Patankar JV, Obrowsky S, Jandl K, et al. 2013. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res 57(10): 1718-1728.
- Hill JO. Melanson EL, Wyatt, HT. 2000. Dietary fat intake and regulation of energy balance: implications for obesity. J Nutr 130: 284-288.
- Boden-albana B, Sacco RL. 2000. Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr. Atheroscler Rep 2: 160-166.
- Tseng YH, Cypess AM, Kahn CR. 2010. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 9: 465–82.
- Park KW, Halperin DS, Tontonoz P. 2008. Before they were fat: adipocyte progenitors. Cell Metab 8: 454–7
- Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, et al. 2012. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150: 366–76.
- Lone J, Choi JH, Kim SW, Yun JW. 2016. Curcumin induces brown fat-like phenotype in 3T3-L1 and primary white adipocytes. J Nutr Biochem 27: 193–202.
- Legette LL, Luna AY, Reed RL, Miranda CL, Bobe G, et al. 2013. Xanthohumol lowers body weight and fasting plasma glucose in obese male Zucker fa/fa rats. Phytochemistry 91: 236–241.
- Yui, K., Kiyofuji, A, Osada, K. 2014. Effects of xanthohumol-rich extract from the hop on fatty acid metabolism in rats fed a high-fat diet. J Oleo Sci 63: 159–168.
- Miyata S, Inoue J, Shimizu M, Sato R. 2015. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (srebp) activation. J Biol Chem 290: 20565–20579.
- Miranda CL. Elias VD, Hay JJ, Choi J, Reed RL, et al. 2016. Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice. Arch Biochem Biophys 599: 22–30.
- Miranda CL, Johnson LA, de Montgolfier O, Elias VD, Ullrich LS, et al. 2018. Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice. Sci Rep 8(1): 613.
- Takahashi K, Osada K. 2017. Effect of Dietary Purified Xanthohumol from Hop (Humulus lupulus L.) Pomace on Adipose Tissue Mass, Fasting Blood Glucose Level, and Lipid Metabolism in KK-Ay Mice. J Oleo Sci 66(5): 531-541.
- Yang J-Y, Della-Fera MA, Rayalam S, Baile CA. 2007. Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis: 12(11): 1953–63.
- Mendes V, Monteiro R, Pestana D, Teixeira D, Calhau C, et al. 2008. Xanthohumol Influences Preadipocyte Differentiation: Implication of Antiproliferative and Apoptotic Effects. J Agric Food Chem 56: (24):11631–7.
- Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.
- Blake R, Trounce IA. 2014. Mitochondrial dysfunction and complications associated with diabetes. Biochim. Biophys. Acta 1840: 1404–1412.
- Costa R, Rodrigues I, Guardão L, Lima JQ, Sousa E. et al, 2017. Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay. Mol Nutr Food Res 61:(4).
- Costa R, Rodrigues I, Guardão L, Rocha-Rodrigues S, Silva C, et al. 2017. Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice. J Nutr Biochem. 45: 39-47.
- Kirkwood JS, Legette LL, Miranda CL, Jiang Y, Stevens JF. 2013. A metabolomics driven elucidation of the anti-obesity mechanisms of xanthohumol. J Biol Chem 288: 19000–19013.